Filing Flows › Protalix BioTherapeutics (PLX) › How it makes money
How Protalix BioTherapeutics (PLX) makes money
Protalix BioTherapeutics (PLX) made $19.9M of revenue in the second quarter 2026 (Q2 2026), +27% from a year earlier. GOODS brought in $19.8M (100%); LICENSE AND R&D SERVICES brought in $68K (0%). Of every dollar of revenue, 23¢ was left as operating profit, 19¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q2 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| GOODS | $19.8M | 99.7% | +167% | +28% |
| LICENSE AND R&D SERVICES | $68K | 0.3% | -100% | -69% |
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $19.9M | 100.0% |
| Operating profit | $4.7M | 23.5% |
| Income tax | $1.1M | 5.4% |
| Net earnings | $3.8M | 19.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $19.9M | +27% |
| Q1 2026 | $33.8M | +234% |
| Q4 2025 | $9.1M | -50% |
| Q3 2025 | $17.9M | -0.6% |
| Q2 2025 | $15.7M | +16% |
| Q1 2025 | $10.1M | +170% |
| Q4 2024 | $18.2M | +74% |
From Protalix BioTherapeutics' 10-Q filed Aug 12, 2026 (on EDGAR).
Questions
How does Protalix BioTherapeutics make money?
Protalix BioTherapeutics (PLX) made $19.9M of revenue in the second quarter 2026 (Q2 2026), +27% from a year earlier. GOODS brought in $19.8M (100%); LICENSE AND R&D SERVICES brought in $68K (0%). Of every dollar of revenue, 23¢ was left as operating profit, 19¢ was left as net earnings.
What is Protalix BioTherapeutics' biggest business?
GOODS: $19.8M in the second quarter 2026, 100% of revenue, +28% from a year earlier.
What is Protalix BioTherapeutics' profit margin?
Net earnings were $3.8M, 19.0% of revenue, in the second quarter 2026; the operating margin was 23.5%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.